Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated
non-small cell lung cancer (NSCLC). Second-and third-generation ALK inhibitors are …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

Drug-induced interstitial lung disease (DI-ILD) is a rare adverse event associated with
targeted therapies that inhibit the anaplastic lymphoma kinase (ALK) protein. Although …

Introduction We evaluated the incidence of pneumonitis in clinical trials of anaplastic
lymphoma kinase (ALK) inhibitors in patients with advanced non-small cell lung cancer …

Background: Crizotinib, an oral tyrosine kinase inhibitor that targets anaplastic lymphoma
kinase, has proven to offer sustained progression-free survival in anaplastic lymphoma …

Introduction Interstitial lung disease (ILD) is a rare, but potentially serious, side effect
associated with crizotinib, a tyrosine kinase inhibitor for anaplastic lymphoma kinase …

Background Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor
approved by the US Food and Drug Administration to treat crizotinib-refractory non-small cell …

We present a 45-year-old patient diagnosed with anaplastic lymphoma kinase (ALK)-
rearranged metastatic lung cancer who developed grade 4 interstitial lung disease (ILD) …

Tumorigenic rearrangements in anaplastic lymphoma kinase (ALK) account for 3–7% of all
non-small cell lung cancers (NSCLC). Treatment with targeted tyrosine kinase inhibitors …

Background If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is
identified, ALK‐tyrosine kinase inhibitors (ALK‐TKIs) can be an effective treatment …